Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Vector BioMed Selected as Top Lentiviral Vector Design and Manufacturing Company
Life Sciences Review recognizes the pure-play lentiviral vector company’s work to help Asia-Pacific healthcare providers manufacture CAR-T therapies closer to patients.
GAITHERSBURG, Md., Nov. 9, 2026 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced that it has been named Lentiviral Vector Design and Manufacturing Company of the Year in Asia 2026 by Life Sciences Review. The recognition highlights the company’s specialized lentiviral vector expertise and its work helping healthcare providers around the world develop and deliver advanced cell and gene therapies closer to where patients live. [Read more…]
Celaid Therapeutics Raises JPY 400 million in Series B Financing to Advance Ex Vivo Hematopoietic Stem Cell (HSC) Expansion
For decades, hematopoietic stem cell transplantation (HSCT) has been one of the most successful cell therapies in medicine, with more than 40,000 transplants performed worldwide each year. Yet the field has a stubborn problem: not every patient who needs a transplant can get one. Ex vivo hematopoietic stem cell (HSC) expansion was designed to solve it, but progress has been slow. Only a handful of companies have pursued the approach, including Gamida Cell in Israel, ExCellThera in Canada, and Plasticell in the United Kingdom. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2027
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
Evia Bio® Announces Availability of GMP-Grade CellShield™ MSC DMSO-Free Cryopreservation Media
MINNEAPOLIS, MN – October 28th, 2026 – Evia Bio®, a leading provider of non-dimethyl sulfoxide (non-DMSO) cryopreservation solutions for the cell therapy and in vitro fertilization industries, today announced the GMP grade of CellShield™ cryopreservation media is now available for product shipment to customers.
The CellShield product line is DMSO-free and includes a controlled rate freezing program that optimizes viability, recovery and functionality. GMP grade CellShield MSC is now available for purchase via the Evia Bio website and direct shipment from the manufacturer. [Read more…]
- 1
- 2
- 3
- …
- 146
- Next Page »